Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease. (30th June 2016)

• Record Type: Journal Article
• Authors: Cover, Keith S.; van Schijndel, Ronald A.; Versteeg, Adriaan; Leung, Kelvin K.; Mulder, Emma R.; Jong, Remko A.; Visser, Peter J.; Redolfi, Alberto; Revillard, Jerome; Grenier, Baptiste; Manset, David; Damangir, Soheil; Bosco, Paolo; Vrenken, Hugo; van Dijk, Bob W.; Frisoni, Giovanni B.; Barkhof, Frederik
• Is Part Of: Psychiatry research. Volume 252(2016)
• Page Start: 26
• Page End: 35
• Publication Date: 2016-06-30
• Subjects: Hippocampus -- Atrophy -- Manual segmentation -- Automatic segmentation -- Magnetic resonance imaging -- Mild cognitive impairment -- Alzheimer disease -- Boundary shift integral; Psychiatry -- Periodicals; Brain -- Imaging -- Periodicals; Psychiatry -- Periodicals; Diagnostic Imaging -- Periodicals; Psychiatrie -- Périodiques; Cerveau -- Imagerie pour le diagnostic -- Périodiques; 616.890754
• DOI: 10.1016/j.pscychresns.2016.04.006
• Languages: English
• ISSNs: 0925-4927

Abstract

Abstract: The purpose of this study is to assess the reproducibility of hippocampal atrophy rate measurements of commonly used fully-automated algorithms in Alzheimer disease (AD). The reproducibility of hippocampal atrophy rate for FSL/FIRST, AdaBoost, FreeSurfer, MAPS independently and MAPS combined with the boundary shift integral (MAPS-HBSI) were calculated. Back-to-back (BTB) 3D T1-weighted MPRAGE MRI from the Alzheimer's Disease Neuroimaging Initiative (ADNI1) study at baseline and year one were used. Analysis on 3 groups of subjects was performed – 562 subjects at 1.5 T, a 75 subject group that also had manual segmentation and 111 subjects at 3 T. A simple and novel statistical test based on the binomial distribution was used that handled outlying data points robustly. Median hippocampal atrophy rates were −1.1%/year for healthy controls, −3.0%/year for mildly cognitively impaired and −5.1%/year for AD subjects. The best reproducibility was observed for MAPS-HBSI (1.3%), while the other methods tested had reproducibilities at least 50% higher at 1.5 T and 3 T which was statistically significant. For a clinical trial, MAPS-HBSI should require less than half the subjects of the other methods tested. All methods had good accuracy versus manual segmentation. The MAPS-HBSI method has substantially better reproducibility than the other methods considered. Highlights: Compared the reproducibility of methods for measuring hippocampal atrophy rates. Compared FreeSurfer, FSL/FIRST, MAPS-HBSI, AdaBoost and manual. Back-to-back MPRAGEs at baseline and year one for N=562 ADNI1 1.5 T subjects. Used a novel but simple statistical test that is robust to outlying data points. MAPS-HBSI should require half the subjects in a clinical trial than others tested.